However, pharmacological EZH2 inhibition in tumor cell lines has also been shown to upregulate cell surface expression of the NK cell-inhibitory ligand MHC-I, following treatment with GSK503 or EPZ011989 (93, 94). Here, EZH2 is linked to neoplasm.